CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin.
antibody-drug conjugate
cellular crosstalk
extracellular vesicle
immune therapy
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2021
accepted:
07
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
CD30, a member of the TNF receptor superfamily, is selectively expressed on a subset of activated lymphocytes and on malignant cells of certain lymphomas, such as classical Hodgkin Lymphoma (cHL), where it activates critical bystander cells in the tumor microenvironment. Therefore, it is not surprising that the CD30 antibody-drug conjugate Brentuximab Vedotin (BV) represents a powerful, FDA-approved treatment option for CD30
Identifiants
pubmed: 34395429
doi: 10.3389/fcell.2021.698503
pmc: PMC8362802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
698503Informations de copyright
Copyright © 2021 Lobastova, Lettau, Babatz, de Oliveira, Nguyen, Pauletti, Schauss, Dürkop, Janssen, Paes Leme, Hallek and Hansen.
Déclaration de conflit d'intérêts
HD was employed by the company Pathodiagnostik Berlin MVZ GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2017 Aug 10;130(6):777-788
pubmed: 28596424
Br J Haematol. 2014 Dec;167(5):608-17
pubmed: 25135752
Blood. 2013 Apr 4;121(14):2715-24
pubmed: 23343832
Int J Cancer. 2004 Sep 10;111(4):568-74
pubmed: 15239135
Int J Cancer. 1995 Feb 8;60(4):539-44
pubmed: 7530238
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Semin Immunol. 1998 Dec;10(6):457-70
pubmed: 9826579
Blood. 2019 Jun 13;133(24):2597-2609
pubmed: 30962205
Clin Cancer Res. 2010 Feb 1;16(3):888-97
pubmed: 20086002
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cancer Res. 2002 Jul 1;62(13):3736-42
pubmed: 12097283
Blood. 1985 Oct;66(4):848-58
pubmed: 3876124
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
ACS Nano. 2018 Jan 23;12(1):494-503
pubmed: 29286635
J Immunol. 1996 Oct 15;157(8):3635-9
pubmed: 8871664
J Biol Chem. 2006 Apr 14;281(15):10540-7
pubmed: 16484228
Oncotarget. 2016 May 24;7(21):30523-35
pubmed: 27105521
J Immunol. 2000 Jul 15;165(2):786-94
pubmed: 10878352
J Clin Invest. 2018 Jul 2;128(7):2996-3007
pubmed: 29889102
Leuk Lymphoma. 2017 Jul;58(7):1607-1616
pubmed: 27868471
J Immunol. 1998 Mar 1;160(5):2180-7
pubmed: 9498756
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50
pubmed: 26438866
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
J Pathol. 2014 Mar;232(4):405-14
pubmed: 24659185
Blood. 2015 Feb 26;125(9):1394-402
pubmed: 25573987
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Dev Cell. 2021 Mar 22;56(6):842-859.e8
pubmed: 33756122